Market Cap : 2.66 B | Enterprise Value : 2.22 B | PE Ratio : 26.69 | PB Ratio : 5.08 |
---|
NAS:CORT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:CORT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Corcept Therapeutics's total equity for the quarter that ended in Dec. 2020 was $523.3 Mil.
This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.
* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.
Total Equity and Total Liabilities are the two components for Total Assets.
Corcept Therapeutics's Total Equity for the fiscal year that ended in Dec. 2020 is calculated as
Total Equity | = | Total Assets(Q: Dec. 2020 ) | - | Total Liabilities(Q: Dec. 2020 ) |
= | 571.731 | - | 48.393 | |
= | 523.3 |
Corcept Therapeutics's Total Equity for the quarter that ended in Dec. 2020 is calculated as
Total Equity | = | Total Assets(Q: Dec. 2020 ) | - | Total Liabilities(Q: Dec. 2020 ) |
= | 571.731 | - | 48.393 | |
= | 523.3 |
* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.
No Headline